122 related articles for article (PubMed ID: 9855433)
1. Monitoring and safety assessment in Phase I to III clinical trials.
Fescharek R; Nicolay U; Arras-Reiter C
Dev Biol Stand; 1998; 95():203-9. PubMed ID: 9855433
[TBL] [Abstract][Full Text] [Related]
2. A phased approach to clinical testing: criteria for progressing from Phase I to Phase II to Phase III studies.
André FE; Foulkes MA
Dev Biol Stand; 1998; 95():57-60. PubMed ID: 9855414
[TBL] [Abstract][Full Text] [Related]
3. Clinical safety evaluation of combination vaccines.
Midthun K; Horne AD; Goldenthal KL
Dev Biol Stand; 1998; 95():245-9. PubMed ID: 9855438
[TBL] [Abstract][Full Text] [Related]
4. Epidemiological factors in clinical trial design.
Wassilak S
Dev Biol Stand; 1998; 95():75-83. PubMed ID: 9855417
[TBL] [Abstract][Full Text] [Related]
5. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
6. Safety monitoring in vaccine development and immunization.
Lee CJ; Lee LH; Lu CH; Huang YJ; Chu ML
Acta Paediatr Taiwan; 2006; 47(1):7-13. PubMed ID: 17016963
[TBL] [Abstract][Full Text] [Related]
7. How to improve the clinical development paradigm and its division into phases I, II and III.
Bamberger M; Moore N; Lechat P;
Therapie; 2011; 66(4):331-4, 327-30. PubMed ID: 21851796
[TBL] [Abstract][Full Text] [Related]
8. Clinical trials.
Farrington P; Miller E
Methods Mol Med; 2003; 87():335-52. PubMed ID: 12958466
[No Abstract] [Full Text] [Related]
9. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
10. A global perspective on vaccine safety.
Duclos P
Vaccine; 2004 May; 22(15-16):2059-63. PubMed ID: 15121323
[TBL] [Abstract][Full Text] [Related]
11. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials.
Thall PF; Russell KE
Biometrics; 1998 Mar; 54(1):251-64. PubMed ID: 9544520
[TBL] [Abstract][Full Text] [Related]
12. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
Lunsford LD; Flickinger JC; Larson D
Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
[TBL] [Abstract][Full Text] [Related]
13. Critical assessment of international clinical development programmes for new antihypertensive drugs.
Ménard J
J Hypertens Suppl; 1993 Dec; 11(5):S39-46. PubMed ID: 8158432
[TBL] [Abstract][Full Text] [Related]
14. New vaccine technologies.
Wood DJ
Dev Biol (Basel); 2002; 111():285-90. PubMed ID: 12678251
[TBL] [Abstract][Full Text] [Related]
15. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
16. Statistical, epidemiological, and risk-assessment approaches to evaluating safety of vaccines throughout the life cycle at the Food and Drug Administration.
Ball R; Horne D; Izurieta H; Sutherland A; Walderhaug M; Hsu H
Pediatrics; 2011 May; 127 Suppl 1():S31-8. PubMed ID: 21502249
[TBL] [Abstract][Full Text] [Related]
17. Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team.
Crowe BJ; Xia HA; Berlin JA; Watson DJ; Shi H; Lin SL; Kuebler J; Schriver RC; Santanello NC; Rochester G; Porter JB; Oster M; Mehrotra DV; Li Z; King EC; Harpur ES; Hall DB
Clin Trials; 2009 Oct; 6(5):430-40. PubMed ID: 19846894
[TBL] [Abstract][Full Text] [Related]
18. Safety considerations for new vaccine development.
Ellenberg SS
Pharmacoepidemiol Drug Saf; 2001; 10(5):411-5. PubMed ID: 11802587
[TBL] [Abstract][Full Text] [Related]
19. Safety experience with heptavalent pneumococcal CRM197-conjugate vaccine (Prevenar) since vaccine introduction.
Center KJ; Strauss A
Vaccine; 2009 May; 27(25-26):3281-4. PubMed ID: 19200818
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic vaccine trails in Thailand.
Churdboonchart V
J HIV Ther; 2004 Sep; 9(3):57-9. PubMed ID: 15534562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
